Correlation of Her-2/neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast Carcinoma
Authors:
- 1 July 2005
- journal article
- research article
- Published by Hindawi Limited in The Breast Journal
- Vol. 11 (4) , 278-280
Abstract
The purpose of this study was to determine if any relationship exists between Her-2/neu gene amplification and estrogen receptor (ER), progesterone receptor (PR), MIB-1, grade, size and age in female breast cancer. Five hundred and eighteen female patients with invasive breast carcinoma, 390 ductal and 128 lobular, in which assessment of Her-2/neu amplification by fluorescence in-situ hybridization (FISH) has been performed, were reviewed retrospectively. Each patient was further assessed for ER, PR, MIB-1, grade, size and age at diagnosis. Chi-square analysis was then used to correlate the above observations. Overall gene amplification was seen in 76 (15%) of the cases, 68 (17%) were ductal and 8 (6%) were lobular. Her-2/neu gene was amplified in 37 (10%) out of 379 ER positive cases and in 39 (28%) out of 139 ER negative cases. Her-2/neu was amplified in 22 (7%) out of 301 PR positive cases and in 54 (25%) out of 217 PR negative cases. Amplification occurred in 18 (8%) out of 222 negative MIB-1 cases and amplified in 58 (20%) out of 296 positive cases. Amplification was seen in 5 (10%) out of 49 grade I tumors, 17 (12%) out of 143 grade II tumors and 54 (27%) out of 198 grade III tumors. Lobular carcinomas were not graded. Amplification was present in 52 (15%) out of 346 T1 lesions, in 17 (13%) out of 130 T2 lesions, in 5 (17%) out of 30 T3 lesions and in 2 (17%) out of 12 T4 lesions. Her-2/neu was amplified in 67 (14%) out of 467 woman 41 years and older, and in 9 (18%) out of 51 women 40 years and younger. Comparison of these frequencies using chi-square test revealed statistically significant correlation between Her-2/neu amplification and ductal versus lobular carcinoma (p<0.0003), ER (p=0.0001) and PR (p<0.0001) negative tumors, over-expression of MIB-1 (p<0.0005) and high tumor grade (p=0.0009), while size of the tumor (p=0.08) and age of the patients (p=0.67) were not statistically significant. Correlation was found between Her-2/neu amplification and tumor type, high histological grade, ER and PR negative tumors, and high proliferative MIB-1 index. No correlation was found between size of the tumor and age of the patient with Her-2/neu amplification.Keywords
This publication has 16 references indexed in Scilit:
- Ki‐67 expression in breast carcinomaCancer, 2003
- HER2/neuAmplification in Breast CancerAmerican Journal of Clinical Pathology, 2002
- Should Selection of Adjuvant Chemotherapy for Patients With Breast Cancer Be Based on erbB-2 Status?JNCI: Journal of the National Cancer Institute, 1998
- Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosisInternational Journal of Cancer, 1997
- Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: An immunohistochemical study including correlations with p53, c‐erbB‐2 and estrogen receptor statusPathology International, 1996
- Proliferation Markers in Breast Carcinoma:Mitotic Figure Count, S-Phase Fraction, Proliferating Cell Nuclear Antigen, Ki-67 and MIB-1American Journal of Clinical Pathology, 1995
- Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrencesEuropean Journal of Cancer, 1993
- ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.Proceedings of the National Academy of Sciences, 1992
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988